reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data
Open Access
- 25 August 2026
- journal article
- research article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199, 112479
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized TrialsJournal of Clinical Oncology, 2025
- A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best PracticesValue in Health, 2024
- Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapyBlood, 2024
- Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)Journal of Clinical Oncology, 2018
- Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsJournal of Clinical Oncology, 2017
- Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trialsInternational Journal of Clinical Oncology, 2009
- The Validation of Surrogate End Points by using Data from Randomized Clinical Trials: A Case-Study in Advanced Colorectal CancerJournal of the Royal Statistical Society Series A: Statistics in Society, 2003
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical Epidemiology, 1997